NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
In the past week, the Nordic biotech and healthcare stocks declined 1.2% and the Danish stocks alone were down 1.8% despite plenty of exciting news. Ascendis Pharma signed a deal with Novo Nordisk with MUSD 285 in milestone payments and royalties. Further, Y-mAbs Therapeutics announced a license and distribution agreement in Japan for Danyelza, and Acarix announced new orders. Finally, Curasight published a peer-reviewed phase II study with a positive outlook for uTREAT. Additionally, the company just announced brain cancer (high-grade glioma) as the first indication for uTREAT with the first patient to be dosed in Q2 2025.
However, only 9 of the 22 Danish biotech companies had a positive share price development in the past week and just 9 companies have had a positive share price performance year-to-date. Obesity continues to drive the best performances with Gubra, Zealand Pharma, and Pila Pharma having strong YTD performance. Five Danish healthcare stocks with +100% YTD return.
Danish company news
Integrated Delivery Network (IDN) Places Order of the Acarix CADScor System (Link)
Acarix Publishes Third Quarter 2024 Report (Link)
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases (Link)
Biosergen Announces Safety Committee Approval to Proceed with Dose Escalation in Second Cohort for BSG005 Clinical Trial (Link)
Biosergen publishes interim report for third quarter 2024 (Link)
No news the past week
CS MEDICA A/S: CS MEDICA Valued at 17,16 DKK (€2.30 ) per Share Ahead of German IPO, Highlighting Unique Regulatory Position and Growth Potential (Link)
CS MEDICA Expands Presence in Eastern Europe through New Partnership (Link)
Clinical phase II trial of uPAR-PET in brain cancer patients published; data supports development of uTREAT for brain cancer (Link)
No news the past week
No news the past week
No news the past week
No news the past week
Genmab Announces Financial Results for the First Nine Months of 2024 (Link)
Trading statement Q3-2024: Another strong quarter (Link)
No news the past week
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study (Link)
No news the past week
Mexican Application for Tesofensine Not Yet Approved (Link)
No news the past week
No news the past week
ViroGates announces its Interim Report for Q1-Q3 2024: Revenues are disappointing, but strategic refocusing will pave the way for future growth (Link)
Zealand Pharma Announces Financial Results for the First Nine Months of 2024 (Link)
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan (Link)
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments (Link)
No news the past week
Share price development – Danish stocks
On average, the Danish biotech and healthcare stocks delivered a negative return of 1.8% despite many exciting updates. ViroGates rose 56% following their Q3 update, and the stock is now up nearly 200% in the past month. Furthermore, Ascendis Pharma signed a collaboration agreement with Novo Nordisk for the development and commercialization of TransCon-based products within metabolic and cardiovascular diseases. Ascendis Pharma is eligible to receive total payments of up to MUSD 285 in upfront, development, and regulatory milestone payments as well as royalties on sales. Additionally, Acarix announced their Q3 results with 20 new orders in the quarter although it does not have a material impact on the revenue yet. Y-mAbs Therapeutic announced a license and distribution agreement for DANYELZA in Japan, Genmab presented their Q3 results and updated their guidance by increasing the lower end of their revenue and EBIT guidance. Finally, Curasight got a phase II trial of uPAR-PET in brain cancer peer-reviewed with positive outlooks for uTREAT, and this morning the company announced that brain cancer (high-grade glioma) as the first indication for uTREAT with a CTA to be sent in Q1 2025 and the first patient to be dosed in Q2 2025.
Gubra continues to be the best-performing stock year-to-date with a return of 276%. Pila Pharma, Zealand Pharma, Y-mAbs Therapeutic, and ViroGates have also generated returns of over 100% in 2024. Cessatech is at 87%.
Overview of share price development the past week, year-to-date, and the last twelve month
Nordic Biotech & Healthcare Developments
In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) declined 1.2% to 63,35. The healthcare index has had a strong performance since the beginning of October last year although it has partly been offset by a few months of poor performance leading to a 5% increase in the past year. The index has performed better than the KPNGX index. However, since August the performance gap has narrowed between them, and the index is still behind the large-cap indices.
The Nordic healthcare stocks (KPHC) vs. C25, S30, and KPNGX the past year
The top three best-performing stocks in the past week
ViroGates (56%) is active in medical technology. Today, business operations are conducted in research and development of biomarkers and diagnostic instruments for the healthcare industry. The products are sold under different brands and are used for identification, analysis, and further treatment of diseases, mainly cardiovascular diseases, cancer, and neurological diseases.
Audientes (49%) is a Danish technology company specialising in the development of hearing aids. Audientes’ hearing aid solution, Ven™ by Audientes, is available in the Indian market, online and through retailers. Audientes’ vision is to develop products that can be used by people suffering from hearing loss who currently do not have access to a solution for their hearing loss.
Odinwell (39%) is a medtech company. The company specializes in the development of medical devices that are addressed to wound care management. The company is developing a platform for wound care with associated technological aids to analyze and facilitate the process around wound care management. In addition to the main business, associated services are also offered.
Resources: Refinitiv Eikon, Cision, Nordnet & company websites
